Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO Committee turns...

    CDSCO Committee turns down Novartis FDC drug including Vildagliptin, Metformin, Glimepiride

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-11T17:38:33+05:30  |  Updated On 16 Aug 2021 12:12 PM IST

    New Delhi: The Swiss drugmaker, Novartis recently presented before the Central Drugs Standard Control Organization(CDSCO) Technical Committee to seek approval manufacture and market its Fixed-Dose Combination of Vildagliptin 50mg + Metformin 850mg + Glimepiride 2.mg Tablets. However, the committee rejected to grant permission for the same while agreeing with the recommendations of the Subject Expert Committee (Endocrinology & Metabolism).


    The proposed FDC drug is indicated for an adjunct to diet and exercise in patients inadequately controlled with the Metformin and sulfonylurea.


    Initially firm's proposal was taken up by the SEC wherein the committee opined that there is no rationality in combining two insulin secretagogues in one FDC. Moreover, the committee also noted that the clinical study data presented by the firm is not on the proposed FDC. Further, the firm informed the committee that proposed FDC is not marketed anywhere in the world. Hence, the committee did not recommend for the proposed FDC.


    After three months, the firm's proposal was once again deliberated by the SEC Committee following the company's response.


    The CDSCO committee opined that although SU & DPP-IV inhibitors act differently, the outcome of both the drugs is to stimulate insulin secretion. The justification that this FDC will be useful for patients who require 3 drugs as add-on therapy and hence FDC of the 3 drugs will be useful was not justified with adequate data. The clinical trial data presented is on the 3 drugs given as add-on therapy and not with the proposed FDC. The committee also noted that the proposed FDC is not approved in any country. In view of the above, committee after detailed deliberation reiterated its earlier stand and didn't recommend approval of the proposed FDC.


    Also Read: CDSCO denies approval for Akums Acid reflux FDC in Capsule form


    Justification submitted by the firm:-




    • In fact, as per lQVlA September 2018 data, as many as 16% prescriptions of OADs comprise of triple drugs. The report also suggests that 40% co-prescriptions of Galvus (Vildagliptin) are with a SU + Metformin and 22% co-prescriptions of GalvusMet (Vildagliptin + Metformin) are with a SU. This data is indicative and conclusive of the fact that 50% of patients are presently already on a Vildagliptin (DPP-4 inhibitor) + Metformin + SU.



    • The guidelines recommend adding a DPP-4 inhibitor to Metfoi min and SU or, a SU to Metformin + DPP4 inhibitor combination in case of inadequate glycemic control while on either of the combinations and it is evident from lQVlA data that a significant number of prescriptions are of triple drugs.



    • The proposed FDC will ensure improved adherence for achievements of long-term treatment goals. Polypharmacy with increased pill burden and dosing frequency are identified as factors responsible for poor adherence to oral hypoglycemic therapy. In a study of 2741 patients on an oral antidiabetic drug (OAD), there was an inverse relationship between OAD adherence and HbA1c; controlling for baseline HbA1c and therapy regimen, each 10% in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (=°0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the nonadherent ones.


    The firm presented their proposal before the CDSCO Technical committee which after detailed deliberation, agreed with the recommendation of the Subject Expert Committee (Endocrinology & Metabolism) and did not recommend for approval of the proposed FDC.


    Also Read: CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

    additional drugCDSCOcombo drugdiet supplementendocrinologyexercise drugfdc drugFixed Dose Combinationfixed dose combinationsGlimepirideMetforminNovartisSEC CommitteesulfonylureaVildagliptin

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok